Skip to main content

Advertisement

Table 6 Baseline characteristics per dosage used for each group

From: Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature

Group A*   Fixed prophylactic dose (n = 26) Higher prophylactic (weight/anti-Xa-adjusted) (n = 16) Full treatment dose (n = 34) p-value
Mean age at enrolment 32.23 ± 4.39, 32, 30–35 33.94 ± 3.94, 32.5, 31–37 33.06 ± 4.31, 33, 30–36 0.5021
BMI 23.02 ± 2.85, 22.86, 20.76–23.88 26.03 ± 3.62, 25.37, 23.66–28.65 25.98 ± 5.01, 24.45, 21.88–29.38 0.0101
Mean duration of LMWH use 8.82 ± 1.46, 9.5, 9–9.5 9.17 ± 1.25, 9, 9–10 8.34 ± 1.98, 9, 8–9.5 0.1560
No of foetuses at the observed gestation 1.04 ± 0.2, 1, 1–1 1.06 ± 0.25, 1, 1–1 1.03 ± 0.17, 1, 1–1 0.8560
High risk thrombophilia (Positives,% in group) 4, 15.38% 3, 18.75% 12, 35.29% 0.1706
APA status (successful tests N = 54) (N positive/N negative, % in treatment type) 7/22, 31.82% 2/11, 18.18% 7/21, 33.33% 0.6440
History of VTE
 Unprovoked 6 5 8 0.4238
 Provoked by combined oral contraceptives 20 11 26
Concomitant ASA use (Positives,% in group) 3, 11.54% 3, 18.75% 5, 14.71% 0.8111
Group B*   Fixed dose prophylactic (n = 262) Higher prophylactic (n = 144) Therapeutic (n = 39) p-value
Mean age at enrolment 33.43 ± 4.43, 34, 31–36 34.08 ± 4.75, 34, 31–37 32.31 ± 4.92, 33, 29–36 0.2326
BMI 23.58 ± 3.19, 23.18, 21.67–24.46 25.45 ± 4.6, 24.94, 21.87–28.28 25.77 ± 4.22, 24.57, 23.18–27.18 <.0001
No of foetuses at the observed gestation 1.02 ± 0.16, 1, 1–1 1.04 ± 0.2, 1, 1–1 1.03 ± 0.16, 1, 1–1 0.2657
Mean duration of LMWH use 8.51 ± 1.53, 9, 8–9 9.09 ± 0.87, 9, 9–10 8.86 ± 0.83, 9, 9–9.5 0.0001
High risk thrombophilia (Positives,% in group) 23, 8.78% 18, 12.50% 4, 10.26% 0.4924
APA status (successful tests N = 196) (N positive/N negative, % in treatment type) 30/126, 23.81% 17/55, 30.91% 10/15, 66.67% 0.0024
History of early pregnancy loss (Positives,% in group) 228, 87.02% 132, 91.67% 36, 92.31% 0.7271
History of IUGR (Positives,% in group) 5, 1.91% 4, 2.78% 1, 2.56%
History of intrauteral fetal death (Positives,% in group) 20, 7.63% 6, 4.17% 2, 5.13%
History of pre-eclampsia/eclampsia 8, 3.05% 2, 1.39% 0
History of placenta abruption/preterm delivery (Positives,% in group) 1, 0.38% 0 0
Concomitant ASA use (Positives,% in group) 34, 12.98% 41, 28.47% 6, 15.38% 0.0005
Group C*   Fixed dose prophylactic (n = 66) Higher prophylactic (n = 51) Therapeutic (n = 15) p-value
Mean age at enrolment 36.18 ± 4.95, 36, 34–39 38.55 ± 5.01, 38, 35–42 36.87 ± 5.3, 37, 32–42 0.0559
BMI 23.71 ± 3.71, 22.86, 21.05–24.978 25.48 ± 3.87, 24.83, 23.03–28.604765 26.34 ± 2.27, 26.3, 24.91–27.89 0.0003
No of foetuses at the observed gestation 1.15 ± 0.36, 1, 1–1 1.27 ± 0.49, 1, 1–2 1.47 ± 0.52, 1, 1–2 0.0278
Mean duration of LMWH use 8.18 ± 2.12, 9, 8.5–9 9.23 ± 1, 9, 9–10 9.17 ± 0.45, 9, 9–9.5 0.0007
High risk thrombophilia (Positives,% in group) 5, 7.58% 5, 9.80% 3, 20.00% 0.3456
APA status (successful tests N = 59) (N positive/N negative, % in treatment type) 10/33, 30.30% 6/20, 30.00% 0/6, 0% 0.2885
Concomitant ASA use (Positives,% in group) 18, 27.27% 20, 39.22% 2, 13.33% 0.1194
Group D*   Fixed dose prophylactic (n = 86) Higher prophylactic (n = 61) Therapeutic (n = 18) p-value
Mean age at enrolment 31.33 ± 4.38, 31, 29–34 33.49 ± 4.35, 34, 31–36 34.61 ± 3.42, 34.5, 32–37 0.0007
BMI 23.68 ± 2.68, 23.57, 21.87–25.65 24.09 ± 4.26, 23.12, 21.21–25.34 29.3 ± 7.21, 27.59, 24.51–33.13 0.0004
No of foetuses at the observed gestation 1.02 ± 0.15, 1, 1–1 1.07 ± 0.25, 1, 1–1 1.06 ± 0.24, 1, 1–1 0.4385
Mean duration of LMWH use 8.15 ± 1.63, 9, 8–9 8.6 ± 1.37, 9, 9–9 8.06 ± 2.17, 9, 9–9 0.0521
High risk thrombophilia (Positives,% in group) 7, 8.14% 7, 11.48% 3, 16.67% 0.5181
APA status (successful tests N = 54) (N positive/N negative, % in treatment type) 3/26, 11.54% 8/26, 30.77% 0/2, 0% 0.1742
Family History of VTE (Positives,% in group) 48, 55.81% 21, 34.43% 4, 22.22% 0.0003
Asymptomatic Thrombophilia 22, 25.58% 21, 34.43% 2, 11.11%
Increased resistance in uterine arteries (Positives,% in group) 2, 2.33% 0 0
Reasons not specified (Positives,% in group) 14, 16.28% 19, 31.15% 12, 66.67%
Concomitant ASA use (Positives,% in group) 7, 8.14% 13, 21.31% 0 0.0136
  1. * p-value is a) for Kruskal-Wallis for the numerical parameters or b) chi-square for categorical parameters, numerical parameters are reported as: Mean ± SD, Median, 25% quantile −75% quantile75, categorical parameters are reported as N (positive cases), % of positive cases within the treatment type group